As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
CASGEVY® launch acceleration continues, supporting multi-billion-dollar potential- -Broad pipeline supported by leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback